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Early detection of leprosy is key to reduce the ongoing transmission. Antibodies directed against M. 
leprae PGL-I represent a useful biomarker for detecting multibacillary (MB) patients. Since efficient 
leprosy diagnosis requires field-friendly test conditions, we evaluated two rapid lateral flow assays (LFA) 
for detection of Mycobacterium leprae-specific antibodies: the visual immunogold OnSite Leprosy Ab 
Rapid test [Gold-LFA] and the quantitative, luminescent up-converting phosphor anti-PGL-I test [UCP-
LFA]. Test performance was assessed in independent cohorts originating from three endemic areas. In 
the Philippine cohort comprising patients with high bacillary indices (BI; average:4,9), 94%(n = 161) 
of MB patients were identified by UCP-LFA and 78%(n = 133) by Gold-LFA. In the Bangladeshi cohort, 
including mainly MB patients with low BI (average:1), 41%(n = 14) and 44%(n = 15) were detected by 
UCP-LFA and Gold-LFA, respectively. In the third cohort of schoolchildren from a leprosy hyperendemic 
region in Brazil, both tests detected 28%(n = 17) seropositivity. Both rapid tests corresponded well with 
BI(p < 0.0001), with a fairly higher sensitivity obtained with the UCP-LFA assay. However, due to the 
spectral character of leprosy, additional, cellular biomarkers are required to detect patients with low 
BIs. Therefore, the UCP-LFA platform, which allows multiplexing with differential biomarkers, offers 
more cutting-edge potential for diagnosis across the whole leprosy spectrum.
Leprosy, an infectious disease caused by Mycobacterium leprae (M. leprae), still poses a major health threat in 
developing countries. The availability of effective multi-drug therapy (MDT) has decreased the global disease 
burden significantly, however, the annual new case detection rate has remained virtually stable during the past 
decade which undeniably points towards the continuation of bacterial transmission. Mis- or delayed diagnosis 
frequently occurs as leprosy diagnosis still relies on clinical symptoms1. These symptoms typically take 2–6 years, 
but also up to 20 years, to become manifest2. Moreover, as the majority of people have sufficient natural immunity 
to (myco)bacterial infection and will not progress to disease3, a small proportion (1–5%) of M. leprae infected 
individuals will actually develop clinical symptoms. During subclinical M. leprae infection the host, without being 
aware of the infectious state, may transmit the bacteria, allowing transmission to continue, especially among close 
contacts of the infected individuals4, 5. Diagnostic tests for early detection of leprosy, allowing adequate treatment 
of early-stage leprosy and M. leprae infection, could therefore make significant differences in transmission and 
clinical outcomes.
Leprosy presents as a spectral disease, ranging from a dominant cellular phenotype with the ability to mount 
a cellular response that leads to effective killing of M. leprae, to an immune response characterized mostly by 
humoral immunity against M. leprae6. Within the leprosy spectrum five disease types can be identified according 
to the Ridley Joplin classification7: tuberculoid (TT), borderline tuberculoid (BT), borderline (BB), borderline 
lepromatous (BL) and lepromatous leprosy (LL). Alternatively, the WHO classification is based on the number 
of skin lesions and nerve involvement and classifies leprosy as multibacillary (MB; > 5 lesions) or paucibacillary 
(PB; ≤ 5 lesions)2 in which PB is predominantly associated with the cellular phenotype and MB with the humoral 
immune response.
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A useful biomarker for leprosy, predominantly for MB patients, is the level of IgM antibodies directed against 
the M. leprae-specific phenolic glycolipid I (PGL-I)8, 9. Moreover, upon effective treatment of leprosy IgM levels 
drop and can therefore be used to monitor efficacy of leprosy treatment10.
Leprosy endemic areas are often short of sophisticated laboratories which makes it imperative to develop 
diagnostic tests for the detection of PGL-I antibodies suitable for field settings. The aim of this study was to eval-
uate two recently designed field-friendly lateral flow assays (LFAs), the OnSite Leprosy Ab Rapid test11 and the 
in-house developed PGL-I up-converting phosphor (UCP)-LFA12.
The OnSite Leprosy Ab Rapid test is an immunochromatographic LFA, detecting IgM antibodies against 
PGL-I and IgG antibodies to LID-1. The latter fusion protein, encoded by the genes for ML0405 and ML2331, has 
been shown to be a useful diagnostic marker for MB leprosy13, 14.
UCP-LFAs have previously demonstrated applicability for detection and monitoring of a variety of ana-
lytes15–17, including cellular biomarkers for Mycobacterium tuberculosis18, 19. Therefore, we developed user-friendly 
UCP-LFAs for the detection of IgM antibodies against PGL-I, which proved robust in multiple (field) studies10, 12, 20. 
The luminescent UCP-label enables quantitative determination of IgM levels using portable readers, whereas 
the colloidal gold label of the OnSite Leprosy Ab Rapid test (Gold-LFA) generates qualitative results which are 
visually inspected. Test performance of these two different field-friendly LFA formats was assessed using identical 
sera of 3 cohorts derived from different leprosy endemic areas in the Philippines, Bangladesh and Brazil.
Results
Performance of UCP-LFA and Gold-LFA in selected, polar leprosy patients. To analyze the per-
formance of the UCP-LFA and the Gold-LFA, we first analyzed a selection of Philippine polar leprosy patients 
(cohort 1, n = 200). MB patients (n = 171) could be adequately distinguished from nonendemic controls (NEC; 
n = 5) using the UCP-LFA (AUC:1; cut-off:0.29, sensitivity: 94%, specificity: 100%) or the Gold-LFA (AUC:0.89; 
cut-off:0.5, sensitivity: 78%, specificity: 100%) (Fig. 1A). In the PGL-I ELISA, 145 out of 171 MB patients (85%) 
were positive (Fig. 1B). The UCP-LFA identified 161 (94%) MB patients as positive, whereas for 133 (78%) MB 
patients a positive test band was observed in the Gold-LFA. Furthermore, all 5 NEC included as negative controls 
were confirmed negative in both Gold-LFA and UCP-LFA.
Of the 24 PB patients, one (4%) was positive in the PGL-I ELISA, 2 (8%) in the Gold-LFA and 4 (17%) in the 
UCP-LFA (Fig. 1B). With respect to disease classification both tests distinguished MB and PB patients very well, 
providing an AUC of 0.94 for the UCP-LFA (sensitivity: 94%; specificity: 81%) and 0.87 for the Gold-LFA (sensi-
tivity: 78%; specificity: 94%) (Fig. 1A).
Assessment of test concordance showed that the majority (n = 133; 78%) of MB patients were detected by both 
LFAs, whereas 28 (16%) were identified by UCP-LFA only (Fig. 1C; Supplementary Figure S2). Of these 28 indi-
viduals, 22 (79%) showed ELISA values around the cut-off (0.1–0.5), indicating sensitive detection of low PGL-I 
positives. Out of 24 PB patients one was positive in both tests, one in the Gold-LFA only, 3 in the UCP-LFA only 
and 19 were negative in both tests.
In summary, although some samples showed discordant results between the 2 tests (Supplementary Figure S2) 
in the Philippine cohort both LF-based tests identified the majority of MB patients (≥78%) and could distinguish 
MB patients from PB patients or NEC.
Test performance of UCP-LFA and Gold-LFA in a Bangladeshi cohort. Since both LFAs performed 
well in cohort 1, which was selected to include polar types of leprosy, we next evaluated test performance in an 
unbiased population characterized by representation of less polar forms of leprosy and MB patients with low BIs, 
consisting of leprosy patients, healthy household contacts (HHC) and endemic controls (EC) from Bangladesh 
(Cohort 2). For EC (n = 51), PGL-I seropositivity was detected, 8 (16%) in the PGL-I ELISA, 9 (18%) in UCP-LFA 
and 5 (10%) in the Gold-LFA, resulting in AUCs for MB diagnosis of 0.72 and 0.68 for the PGL-I UCP-LFA and 
Gold-LFA, respectively (Fig. 2A,B). For classification of leprosy into MB or PB, AUCs were comparable, 0.67 for 
the UCP-LFA and 0.64 for the Gold-LFA (Fig. 2A).
14 out of 34 MB patients (41%), the majority of whom had a low or negative BI (Supplementary Figure S1), 
were positive in the PGL-I ELISA, which was similarly reflected in the UCP-LFA (n = 14; 41%) and the Gold-LFA 
(n = 15; 44%) (Fig. 2B). As in the PGL-I ELISA, seropositivity was also observed in both HHC groups (with or 
without BCG vaccination). Besides only a low number in all test groups in cohort 2 being seropositive in either 
of the 2 tests, the PGL-I UCP-LFA and Gold-LFA also detected different seropositive HHC (8 seropositive in 
UCP-LFA only and 2 in Gold-LFA only; Fig. 2C; Supplementary Figure S1), indicating that detection of different 
antibodies in these two test formats can identify different individuals. In patients, 7 MB and 9 PB patients were 
seropositive in either the UCP-LFA or Gold-LFA, of whom 75% (n = 12) showed a weakly positive test response 
(Supplementary Figure S2, Fig. 2C).
Application of UCP-LFA and Gold-LFA in a hyperendemic region in Brazil. Samples of cohort 3 
(n = 60) were collected in a region considered hyperendemic for leprosy in Brazil. Although none of the individ-
uals showed clinical signs of leprosy, both the UCP-LFA and Gold-LFA detected antibodies to M. leprae specific 
antigens in 17 individuals (28%), whereas the conventional ELISA detected antibodies in 11 individuals (18%). 
All individuals seropositive by ELISA were also detected by the UCP-LFA and Gold-LFA. Moreover, the major-
ity of individuals detected by UCP-LFA and Gold-LFA showed concordant results (n = 15), 2 individuals were 
detected by UCP-LFA only and 2 others by Gold -LFA only (supplementary Figure S1) indicating similar test 
performance for the 2 field-friendly assays.
Moreover, we evaluated both test in TB patients, which were all negative showing the lack of cross-reactivity 
at antibody level with other mycobacterial infections (Supplementary Table S1).
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Correlation of lateral flow tests with Bacterial Index. Antibodies against PGL-I and LID-1 are 
reported to predominantly identify MB patients. Consistent with this the majority of MB patients was identified 
in cohort 1 (MB patients with high bacterial index (BI; average: 4,9; range: 3,2–6)), whereas in cohort 2 (MB 
Figure 1. Test performance of UCP-LFA and Gold-LFA in Philippine leprosy patients. Test performance was 
assessed using serum of 171 multibacillary (MB) and 24 paucibacillary (PB) patients. Non-endemic controls 
were included as negative control. (A) Receiver operating characteristics (ROC) curves showing the distinction 
between MB patients and NEC (left panel) and MB and PB patients (right panel) for the UCP-LFA (solid line) 
and Gold-LFA (dotted line). Areas under curve (AUCs) are displayed for both tests. (B) Number and percentage 
of positive individuals per test (ELISA, UCP-LFA, Gold-LFA) are shown for each test group. (C) Venn diagrams 
showing the concordance in positive individuals between UCP-LFA and Gold-LFA per test group.
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Figure 2. Test performance of UCP-LFA and Gold-LFA in a Bangladeshi cohort. Test performance was 
assessed using serum of 34 multibacillary (MB), 45 paucibacillary (PB) patients, 104 healthy household contacts 
(BGC-vaccinated [n = 50], non-vaccinated [n = 54]) and 51 endemic controls (EC). (A) Receiver operating 
characteristics (ROC) curves showing the distinction between MB patients and EC (left panel) and MB and 
PB patients (right panel) for the UCP-LFA (solid line) and Gold-LFA (dotted line). Areas under curve (AUCs) 
are displayed for both tests. (B) Number and percentage of positive individuals per test (ELISA, UCP-LFA, 
Gold-LFA) are shown for each test group. (C) Venn diagrams showing the concordance in positive individuals 
between UCP-LFA and Gold-LFA per test group.
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patients with a low or negative BI (average: 1; range:0–5)) more than half of the MB patients was not seropositive 
in either of the tests (UCP-LFA:56%; Gold-LFA:59%).
Figure 3. Test correspondence with bacterial index. Leprosy patients of which the BI was assessed were 
stratified by bacterial index (BI negative [n = 53] and positive [n = 145]) to evaluate the correlation between BI 
and LF test results. (A) ELISA data stratified by BI, the cut-off of OD450-background (=0.2) is visualized by the 
dotted line. 125 BI+ patients and 6 BI− patients showed a positive result in ELISA. Values significantly differed 
between BI− and BI+ patients (p < 0.0001) (B) UCP-LFA data stratified by BI, the positive cut-off of ratio 0.29 
is visualized by the dotted line. 136 BI+ patients and 9 BI− negative patients showed a positive result in the 
UCP-LFA. Values significantly differed between BI− and BI+ patients (p < 0.0001) (C) Gold-LFA data stratified 
by BI, the cut-off for a positively scored samples (observed test band > 0.5) is visualized by the dotted line. 114 
BI+ patients and 10 BI− patients were scored as positive in the Gold-LFA. Values significantly differed between 
BI−and BI+ patients (p < 0.0001).
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To examine the correlation between the test results and BI, leprosy patients from both cohorts (n = 198) were 
stratified by BI (BI+ [n = 145], BI−[n = 53]). In ELISA, 125 (86%) of BI+ patients showed a positive anti-PGL-I 
titer, in the UCP-LFA 136 (94%) and in the Gold-LFA 114 (78%) (Fig. 3). Of the 53 BI− patients 6 (11%) showed 
a positive anti-PGL-I titer in ELISA, 9 (17%) in the UCP-LFA and 10 (19%) in the Gold-LFA. In all tests, signif-
icantly higher positive values were observed in the BI positive group (p < 0.0001), indicating strong correlation 
with BI and implying the need of other (cellular) biomarkers to diagnose patients with low BI.
Discussion
User-friendly tools to facilitate the diagnosis of leprosy or/M. leprae infection are urgently needed to tackle the 
ongoing transmission. In this study we have compared the UCP-LFA and the OnSite Leprosy Ab Rapid test 
(Gold-LFA), two user-friendly tools for the identification of M. leprae specific humoral immune responses. The 
UCP-LFA detects IgM antibodies directed against PGL-I, whereas the Gold-LFA additionally identifies IgG anti-
bodies directed against LID-1. In a head-to-head comparison of these two LFA tests, the UCP-LFA identified 
similar (cohort 2 [41%] and 3 [28%]) or more (cohort 1 [94%]) MB patients than the Gold-LFA (cohort 1 [78%], 
cohort 2 [44%], cohort 3 [28%]). Especially in MB patients with a positive BI the UCP-LFA turned out to be 
more sensitive than the Gold-LFA, identifying 94% of these patients and outperforming the conventional PGL-I 
ELISA. Despite the similarity in test results between both tests, a number of individuals were detected exclusively 
by either the UCP-LFA (n = 55) or the Gold-LFA (n = 15). On one hand, this discrepancy can be explained by the 
more sensitive quantitative detection of anti-PGL-I IgM in the UCP-LFA due to the use of a luminescence label 
in contrast to a visual, gold label21. On the other hand, though less frequently occurring, seropositivity due to the 
presence of LID-1-specific anti-IgG may detect other samples only in the Gold-LFA. Furthermore, since leprosy 
patients may present only anti-PGL-I IgG and not IgM22 the inclusion of detection of IgG specific for PGL-I in 
diagnostic tests for leprosy should also be considered.
An essential difference between the two antibody tests is the interpretation of test results, whereas the 
UCP-LFA results are objectively measured by a calibrated reader, the Gold-LFA test relies on somewhat more 
subjective visual evaluation by operators. Especially in the field operator differences should be taken into account, 
and re-examination by a second individual is therefore vital. This should be done within 10–15 minutes after the 
test is performed11 to acquire reliable results. In contrast, the UCP-LFA strips can be permanently stored and sent 
to a reference lab for re-analysis.
The use of a reader (Smart Reader) to analyse immunogold LF strips similar to the Gold-LFA test for detection 
of M. leprae-specific antibodies has been described23, 24 and demonstrated that results by visual interpretation and 
results read by Smart Reader agreed moderately (κ index: 0,55)25. However, haemolysis of red blood cells when 
using the immunogold label may hamper accurate measurements and visualisation of low positives, contrary to 
the UCP-LFA format which is a virtually background-free reporter technology21.
In Bangladesh the majority of leprosy patients develop PB leprosy2, which were mostly negative in both LF 
tests used in this study as well as the standard ELISA for detection of antibodies against PGL-I. Moreover, PB 
patients cannot be distinguished from HHC or EC due to the seropositivity observed in these groups. Therefore, 
to identify not only the BI+ MB patients and increase specificity it is imperative to include detection of cellular 
markers in field friendly diagnostic assays for leprosy. Incorporation of the cellular markers IP-10, CCL4 and 
IL-10 into the same UCP-LFA format improved the assay sensitivity for detection of MB as well as PB patients in 
Bangladesh20.
The ability to simultaneously detect both humoral and cellular biomarkers of M. leprae infection in a single 
test, as proved feasible for the UCP-LF format10, can cover the entire spectrum of leprosy, therefore enabling more 
comprehensive diagnosis of leprosy patients.
Materials and Methods
Study participants. Cohort 1. Leprosy patients (LL/BL (n = 127), BT/TT (n = 24) and LL patients (n = 44; 
longitudinal samples of 9 patients), were diagnosed at the Cebu Skin Clinic and Leonard Wood Memorial (LWM) 
Center for Leprosy Research, Cebu, Philippines based on histological findings and clinical observations deter-
mined by experienced leprologists and a leprosy pathologist as previously described8, 13. Patients were categorized 
according to Ridley-Jopling classification7 and bacterial indices (BI) were determined. For some patients, serum 
was also obtained at specified intervals during treatment (at 1, 2, 3, 6, 9 and 12 months), and up to 2 years after the 
start of treatment13. Samples were collected from March 2007 until February 2012. All leprosy patient sera were 
collected at initial diagnosis prior to multidrug therapy (MDT). As a control group, non-BCG-vaccinated, U.S.-
born healthy individuals with no known exposure to either tuberculosis or leprosy were included and designated 
as nonendemic controls (NEC; n = 5).
Cohort 2. Participants were recruited on a voluntary basis between January 2013 and December 2014 in leprosy 
endemic areas in Bangladesh as described previously26. Leprosy was diagnosed based on clinical, bacteriologi-
cal and histological observations as previously described27. Clinical and demographic data were collected in a 
dedicated database. Participants were classified into five test groups: MB patients (n = 34; BL/LL = 8, BT = 26), 
PB patients (n = 45; BT = 41, TT = 4), healthy household contacts (HHC; n = 54) and BCG vaccinated HHC 
(HHC&BCG; n = 50) selected as previously described20. Control individuals without clinical disease symptoms 
from the same leprosy endemic area (endemic controls, EC; n = 51) were examined for the absence of clinical 
signs and symptoms of leprosy and tuberculosis. Staff of leprosy- or TB clinics were excluded as EC.
Cohort 3. Serum samples of schoolchildren were collected in the state of Pará, Brazil (n = 60), considered hyper-
endemic for leprosy (new case detection >4.0 per 10,000 population) as previously described28. Serum samples 
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from all sources were coded to protect donor identities and were obtained with informed consent and/or with 
permission from the respective institutional review boards of each country.
Synthetic PGL-I. The disaccharide epitope (3,6-di-O-methyl-β-D-glucopyranosyl(1→4)2,3-di-O- 
methylrhamnopyranoside) of M. leprae specific native PGL-I glycolipid was synthesized and coupled to human 
serum albumin (synthetic PGL-I; designated ND-O-HSA, approximately 40 disaccharides per molecule)19. It was 
obtained through the Biodefense and Emerging Infections Research Resources Repository (http://www.beire-
sources.org/TBVTRMResearchMaterials/tabid/1431/Default.aspx).
PGL-I ELISA. Antibodies (IgM, IgG, IgA) against M. leprae PGL-I were detected by ELISA. Briefly, 200 ng 
ND-O-HSA was coated per well in 50 µl in 0.1 M Na2CO3/NaHCO3 buffer (pH 9.6) at 4 °C overnight. After block-
ing with 200 µl PBS/1%BSA/0.05% Tween 80 per well for 1 hour, 50 µl of 1:400 diluted sample was added and 
incubated for 2 hours at room temperature. Then, 50 µl of a 1:8000 dilution of anti-human IgG/IgM/IgA-HRP, 
(Dako P0212) in 0.05%Tween 20/PBS was incubated for 2 hours. In between each step the wells were washed 3 
times with PBS/0,05% Tween 20. 50 µl of 3,3′,5,5′-Tetramethylbenzidine (TMB) was added and the color reaction 
was stopped using H2SO4 after 10–15 minutes. Absorbance was determined at a wavelength of 450 nm. Samples 
with an optical density at 450 nm (OD450) after correction for background OD (0,1%BSA in coating buffer) above 
0.200 were considered positive. This threshold was determined by a threefold multiplication of an average NEC 
value.
The OnSite Leprosy Ab Rapid test. The OnSite Leprosy Ab Rapid test11 was purchased from CTK Biotech (San 
Diego, CA) and used according to the manufacturer’s instructions. Test band intensity was independently scored 
ranging from 0.5 to 4 by two independent individuals, in case of differences between operators the highest rated 
score was used11. The OnSite Leprosy Ab Rapid test is referred to as the Gold-LFA in this study.
PGL-I UCP-LFA. Anti-PGL-I IgM antibodies were detected as previously described20 using 100-fold diluted 
serum and an IgM-specific UCP conjugate (UCPαIgM). LF strips were scanned in a Packard FluoroCount micr-
otiterplate reader adapted for measurement of the UCP label (980 nm IR excitation, 550 nm emission). Results 
are displayed as the ratio value between Test and Flow-Control signal based on relative fluorescence units (RFUs) 
measured at the respective lines. A threshold for positivity of 0.29 was determined by computing receiver operat-
ing characteristic (ROC) curves20.
Ethics. This study was performed according to the Helsinki Declaration as described previously26. The 
national Research Ethics Committee has approved the study protocol (Ref no. BMRC/NREC/2010–2013/1534 
(Bangladesh) and Ethical Appreciation Certificate N° 26765414.0.0000.0018 (Brazil)). Participants were informed 
about the study-objectives, the samples and their right to refuse to take part or withdraw from the study without 
consequences for their treatment. Written informed consent was obtained before enrolment. Serum samples from 
the Philippines and NEC serum samples are part of a pre-existing collection at Colorado State University (JSS), 
and thus considered exempt from human subjects research. All patients received treatment according to national 
guidelines.
Statistical analysis. Graphpad Prism version 7.00 for Windows (GraphPad Software, San Diego CA, USA) 
was used to perform Mann-Whitney U tests, plot ROC curves and calculate the area under curve (AUC).
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